市场快照
| Study Period: | 2018 - 2026 |
| Base Year: | 2021 |
| CAGR: | 7.5 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
市场概况
导致市场增长的主要因素包括卵巢癌负担的增加和使用联合疗法治疗卵巢癌。55-64岁的女性卵巢癌的发病率很高。卵巢癌的主要症状包括腹胀、盆腔和腹痛、进食困难和泌尿系统症状。据 Globocan 称，2018 年，南非约有 1,371 例新发卵巢癌病例，约有 971 人死于这种疾病。然而，其他因素，例如新兴和低收入经济体缺乏意识，预计将阻碍市场增长。
Scope of the report
As per the scope of the report, Ovarian cancer is a type of cancer that begins in the ovaries. There are several types of ovarian cancer, Epithelial ovarian cancer is the most common type of ovarian cancer. Ovarian cancer is caused by uncontrollable cell growth in the ovarian tissue. It is a growing concern and one of the most common causes of death in women.
| By Cancer Type | |
| Epithelial Ovarian Tumors | |
| Ovarian Germ Cell Tumors | |
| Others |
| By Modality | ||||||||
| ||||||||
|
| Geography | |||||
|
主要市场趋势
CT扫描板块有望在预测期内呈现较好增长
计算机断层扫描 (CT) 是一种成像程序，它使用特殊的 X 射线设备来创建身体内部区域的详细图片或扫描。它也被称为计算机断层扫描和计算机轴向断层扫描 (CAT)。该设备不能很好地显示小的卵巢肿瘤，但他们可以看到较大的肿瘤，并且可能能够看到肿瘤是否正在生长到附近的结构中。它还可以发现肿大的淋巴结、癌症扩散到肝脏或其他器官的迹象，或者卵巢肿瘤正在影响肾脏或膀胱的迹象。此外，随着卵巢癌负担的增加和技术进步，预计将在预测期内推动市场增长。
To understand key trends, Download Sample Report
竞争格局
大多数卵巢癌诊断和治疗产品由全球主要参与者制造。拥有更多研究资金和更好分销系统的市场领导者已经在市场上确立了自己的地位。这有助于市场增长。
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Growing Burden of Ovarian Cancer
-
4.2.2 Use of Combination Therapies for the Treatment of Ovarian Cancer
-
-
4.3 Market Restraints
-
4.3.1 Lack of Awareness in Emerging and Low Income Economies
-
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Cancer Type
-
5.1.1 Epithelial Ovarian Tumors
-
5.1.2 Ovarian Germ Cell Tumors
-
5.1.3 Others
-
-
5.2 By Modality
-
5.2.1 Diagnosis
-
5.2.1.1 Biopsy
-
5.2.1.2 Blood Tests
-
5.2.1.3 Ultrasound
-
5.2.1.4 PET
-
5.2.1.5 CT Scan
-
5.2.1.6 Other Diagnosis
-
-
5.2.2 Therapeutics
-
5.2.2.1 Chemotherapy
-
5.2.2.2 Radiation Therapy
-
5.2.2.3 Immunotherapy
-
5.2.2.4 Hormonal Therapy
-
5.2.2.5 Others
-
-
-
5.3 Geography
-
5.3.1 Middle-East and Africa
-
5.3.1.1 GCC
-
5.3.1.2 South Africa
-
5.3.1.3 Rest of Middle-East and Africa
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Astrazeneca plc
-
6.1.2 Bristol Myers Squibb Company
-
6.1.3 Eli Lilly and Company
-
6.1.4 F. Hoffman-La Roche Ltd
-
6.1.5 Glaxosmithkline Plc
-
6.1.6 Johnson and Johnson (Janssen Pharmaceuticals)
-
6.1.7 Pfizer Inc.
-
6.1.8 Siemens Healthineers AG
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market market is studied from 2018 - 2026.
What is the growth rate of Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market?
The Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market is growing at a CAGR of 7.5% over the next 5 years.
Who are the key players in Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market?
Astrazeneca plc, Bristol Myers Squibb Company, F. Hoffman-La Roche Ltd, Johnson and Johnson (Janssen Pharmaceuticals), Siemens Healthineers AG are the major companies operating in Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market.
